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Key points
 Passive, isolated post-capillary pulmonary hypertension (PH) secondary to left heart disease
may progress to combined pre- and post-capillary or ‘active’ PH
 This ‘activation’ of post-capillary PH significantly increases morbidity and mortality, and is
still incompletely understood.
 In this study, pulmonary vein banding gradually produced post-capillary PH with structural
and functional microvascular remodelling in swine.
 Ten weeks after banding, the pulmonary endothelin pathway was upregulated, likely
contributing to pre-capillary aspects in the initially isolated post-capillary PH.
 Inhibition of the endothelin pathway could potentially stop the progression of early stage
post-capillary PH.
Abstract Passive, isolated post-capillary pulmonary hypertension (IpcPH) secondary to left
heart disease may progress to combined pre- and post-capillary or ‘active’ PH (CpcPH)
characterized by chronic pulmonary vascular constriction and remodelling. The mechanisms
underlying this ‘activation’ of passive pulmonary hypertension (PH) remain incompletely
understood. Here we investigated the role of the vasoconstrictor endothelin-1 (ET) in the
progression from IpcPH to CpcPH in a swine model for post-capillary PH. Swine underwent
pulmonary vein banding (PVB; n = 7) or sham-surgery (Sham; n = 6) and were chronically
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instrumented 4 weeks later. Haemodynamics were assessed for 8 weeks, at rest and during
exercise, before and after administration of the ET receptor antagonist tezosentan. After sacrifice,
the pulmonary vasculature was investigated by histology, RT-qPCR and myograph experiments.
Pulmonary arterial pressure and resistance increased significantly over time. mRNA expression
of prepro-endothelin-1 and endothelin converting enzyme-1 in the lung was increased, while
ETA expression was unchanged and ETB expression was downregulated. This was associated with
increased plasma ET levels from week 10 onward and a more pronounced vasodilatation to in
vivo administration of tezosentan at rest and during exercise. Myograph experiments showed
decreased endothelium-dependent vasodilatation to Substance P and increased vasoconstriction
toKCl inPVB swine consistentwith increasedmuscularizationobservedwithhistology.Moreover,
maximal vasoconstriction toETwas increasedwhereasETsensitivitywasdecreased. In conclusion,
PVB swine gradually developed PH with structural and functional vascular remodelling. From
week 10 onward, the pulmonary ET pathway was upregulated, likely contributing to pre-capillary
activation of the initially isolated post-capillary PH. Inhibition of the ET pathway could thus
potentially provide a pharmacotherapeutic target for early stage post-capillary PH.
(Received 23 February 2018; accepted after revision 11 May 2018; first published online 24 May 2018)
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Introduction
Pulmonary hypertension (PH) is a pathophysiological
disorder that is defined by a mean pulmonary arterial
pressure (mPAP) of>25 mmHg at rest (Galie et al. 2016).
While PH has many different aetiologies, in 65–80%
of all cases PH is due to left heart disease, i.e. WHO
classification group II (Galie et al. 2016; Rosenkranz et al.
2016). In this group of PH, left heart failure (HF), valvular
disease, inflow-/outflow-tract obstructions or congenital
or acquired pulmonary vein stenosis causes an upstream
pressure increase in the pulmonary vasculature. Initially,
this isolated post-capillary PH (IpcPH) is purely passive,
i.e. a direct consequence of the increased pulmonary
venous pressure. However, when left untreated, IpcPH
has the potential to progress to active, combined pre- and
post-capillary PH (CpcPH), a chronic progressive disease
characterized bymarked pulmonary vasoconstriction and
vascular remodelling (Miller et al. 2013; Gerges et al.
2015; Vanderpool & Naeije, 2015) with a worse prognosis
than IpcPH (Tatebe et al. 2012). While IpcPH can be
treated by correcting only the underlying condition (Galie
et al. 2016), CpcPH requires treatment of pulmonary
vascular remodelling as well as the primary disease, as
treatment of the primary disease alone is no longer
able to arrest the progression of CpcPH (Lundgren &
Radegran, 2014). Hence, understanding the time course
of the transition from IpcPH to CpcPH as well as its
underlying mechanism is essential. IpcPH is defined as a
mPAP of >25 mmHg, with a pulmonary capillary wedge
pressure (PCWP) >15 mmHg and a diastolic pressure
gradient (difference between diastolic PAP and PCWP)
<7 mmHg and/or a pulmonary vascular resistance (PVR)
3 Wood units (WU), while CpcPH is defined as a
diastolic pressure gradient of7mmHg and/or a PVR>3
WU (Naeije & D’Alto, 2016). Discriminating IpcPH from
CpcPH requires right heart catheterization to measure
PCWP. Such an invasive procedure is not suitable for a
longitudinal clinical study. In contrast, pre-clinical animal
models for post-capillary PH are available but most
haemodynamic data are acquired at only one or two time
points, often under anaesthesia (Endo et al. 2002; Dai et al.
2004; Garcia-Alvarez et al. 2013; Pereda et al. 2014). In
PH, not only vasoconstriction but potentially also vascular
remodelling may be due to an imbalance between vaso-
constrictors and vasodilators, which may involve down-
regulation of the nitric oxide and prostacyclin pathways,
and upregulation of the endothelin (ET) pathway (Moraes
et al. 2000; Budhiraja et al. 2004). Although changes
in these pathways have been well characterized in both
experimental (Dai et al. 2004; Houweling et al. 2006;
Merkus et al. 2007, 2008; van Duin et al. 2018) and clinical
(Cody et al. 1992; Giaid et al. 1993; Porter et al. 1993;
Cooper et al. 1998; Meoli et al. 2018) studies of PH,
the contribution of alterations in these pathways to the
transition from IpcPH to CpcPH remains incompletely
understood. Here, we hypothesize that the transition
from IpcPH to CpcPH is mediated, at least in part,
by increased activity of the ET pathway. To test this
hypothesis, we investigated the progression of PH using
chronically instrumented swine (De Wijs-Meijler et al.
2016), in a recently developed swinemodel of group II PH
by pulmonary vein banding (PVB) (Garcia-Alvarez et al.
2013; Aguero et al. 2014; Pereda et al. 2014). Repeated
measurements of pulmonary haemodynamics in awake
swine were performed between 5 and 12 weeks after PVB,
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during the progression of PH while evaluating the activity
of the ET pathway. Since exercise testing allows detection
of perturbations in cardiopulmonary function that may
not be apparent under quiet resting conditions, and thus
facilitates the assessment of disease severity (Keusch et al.
2014), we performed measurements both at rest and
during graded treadmill exercise.
Methods
Ethical approval
Studies were performed in accordance with the Guiding
Principles in the Care and Use of Laboratory Animals as
approved by the Council of the American Physiological
Society, and with approval of the Animal Care Committee
of the Erasmus University Medical Centre (EMC3158,
109-13-09). The authors understand the ethical principles
under which The Journal of Physiology operates and this
work complies with the animal ethics checklist outlined
by Grundy (2015).
Sample size calculations
Experiments were designed to minimize the number
of animals used. To calculate minimal sample size, a
power analysis was performed using specialized software
(G∗Power 3.0) (Faul et al. 2007). Assuming a similar
increase in PVR at 3 months post-PVB as in a pre-
vious study (Pereda et al. 2014), and a similar decrease in
PVR after administration of tezosentan as reported pre-
viously (Merkus et al. 2007), a two-tailed approach with
assumed α-error probability of 0.5 and a power of 80%
led to a sample size of n = 5 per experimental group.
Taking into consideration a drop-out of 25% as a result of
(post-)surgical complications, and a 10% drop-out due to
malfunction of the catheters, target group size was set to
n = 8. Thirteen animals completed the protocol and are
included in the final analyses.
Study design
Fifteen crossbred Landrace × Yorkshire swine of either
sex (9 ± 1 kg) underwent non-restrictive inferior
pulmonary vein banding (n = 9) or sham operation
(n = 6). Four weeks later, all 14 surviving animals
(22 ± 1 kg) were chronically instrumented to enable
weekly monitoring of haemodynamics and blood gases
in animals in the awake state. In the following 8 weeks,
animals performed bi-weekly exercise experiments under
control conditions and after administrationof anETA/ETB
receptor antagonist. After 12 weeks, the surviving 13
animals (62 ± 2 kg) were sacrificed and tissues were
harvested.
Pulmonary vein banding
Swine underwent banding of the inferior venous
confluence as described by Pereda et al. (2014). Briefly,
swine were sedated with an intramuscular (I.M.)
injection of tiletamine/zolazepam (5 mg kg−1; Virbac,
Barneveld, The Netherlands), xylazine, (2.25 mg kg−1;
AST Pharma, Oudewater, The Netherlands) and
atropine (1 mg), anaesthetized with intravenous (I.V.)
bolus administration of thiopental (10 mg kg−1;
Rotexmedica, Trittau, Germany), intubated and
ventilated with a mixture of O2 and N2 (1:2) to which
isoflurane (2% v/v; Pharmachemie, Haarlem, The
Netherlands) was added. Animals received antibiotic
prophylaxis prior to the procedure (0.75 ml Depomycine,
200,000 IU ml−1 procainebenzylpenicilline, 200 mg ml−1
dihydrostreptomycine; Intervet Schering-Plough,
Boxmeer, The Netherlands). Under sterile conditions, the
chest was opened via the fifth right intercostal space and
the inferior venous confluence, draining both inferior
pulmonary lobes, was exposed and separated from
surrounding lung tissue using blunt dissection. A surgical
loop (Braun Medical Inc., Bethlehem, PA, USA) was
passed around the vein near the left atrium and secured
at the resting diameter with a silk suture. The ribs were
secured using non-absorbable USP6 braided polyester (Ø
0.8 mm) and the wound was closed in layers using silk
sutures. Anaesthesia was terminated and animals were
extubated once spontaneous ventilation was restored.
Animals received analgesia (0.3 mg buprenorphine I.M.;
Indivior, Slough, UK) and a fentanyl slow-release patch
(6 μg h−1, 48 h) and were transferred back to the animal
facilities once awake. Six swine (8 ± 1 kg) underwent a
sham procedure, performed exactly as described above
where the inferior venous confluence was exposed and
dissected free, but not banded. In the PVB group, one
animal died immediately after the banding procedure
upon commencement of spontaneous breathing, due to
acute pulmonary oedema. Taking humane endpoints into
account, one animal was prematurely euthanized 6 weeks
after banding due to severe HF. Data from these animals
have been excluded from analysis. In the sham group, all
animals survived until the end of follow-up, resulting in
group sizes of n = 7 for PVB and n = 6 for sham.
Chronic instrumentation
Four weeks after PVB or sham procedure, swine were
anaesthetized and ventilated as described above and
chronically instrumented as described previously (De
Wijs-Meijler et al. 2016). Briefly, under sterile conditions,
the chest and pericardium were opened via the fourth
left intercostal space and fluid-filled polyvinylchloride
catheters (Braun Medical Inc.) were inserted into the
aortic arch, the pulmonary artery, the right ventricle
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and the left atrium for blood pressure measurement
and blood sampling. A transit time flowprobe (Trans-
onic Systems Inc., Ithaca, NY, USA) was positioned
around the ascending aorta for measurement of cardiac
output. Catheters were tunnelled to the back and the
chest was closed. Animals were allowed to recover,
receiving a single shot of buprenorphine I.M. (0.3 mg)
and a fentanyl slow-release patch (12 μg h−1, 48 h)
for analgesia and antibiotic prophylaxis consisting of
amoxicillin (25 mg kg−1 I.V.; Centrafarm B.V. Etten-Leur,
TheNetherlands) and gentamycin (5mgkg−1 I.V.; Eurovet,
Bladel, The Netherlands) for seven consecutive days
post-surgery. Once fully awake, animals were transferred
back to the animal facility.
Experimental protocols
Resting haemodynamic measurements were obtained
each week, while exercise studies were performed 6,
8, 10 and 12 weeks following the PVB procedure.
Swine were transferred to a customized, motor-driven
treadmill and the fluid-filled catheters were connected to
pressure transducers (Combitrans pressure transducers,
Braun,Melsungen,Germany). Transducers andflowprobe
were connected to amplifiers and haemodynamics were
recorded at rest and during four-stage incremental
treadmill exercise (1–4 km h−1, 3 min per speed). Heart
rate, cardiac output and left atrial, aortic, right ventricular
andpulmonary arterial bloodpressureswere continuously
recorded and blood samples were collected during the
last 60 s of each 3 min exercise stage, at a time when
haemodynamics had reached a steady state. After 60 min
of rest, at a time when haemodynamics had returned
to baseline, the ETA/ETB receptor antagonist tezosentan
(gift from Dr Clozel, Actelion Pharmaceuticals Ltd) was
administered by an infusion of 300 μg kg−1 min−1 I.V.
After 10minof infusion the exercise protocolwas repeated,
with continuous infusion of 100μg kg−1 min−1 I.V. during
the entire protocol. Due to recurrent crippling, one PVB
animal and one sham animal did not participate in all
exercise experiments, reducing the number of animals to
five in the shamgroup and six in thePVBgroup.Moreover,
due to technical failure, flowprobe data of one PVB animal
were not available, reducing the number of animals to
five for flow-related parameters (cardiac output, stroke
volume, systemic andpulmonary vascular resistance, body
oxygen consumption).
Blood gas measurements
Arterial and mixed venous blood samples were
kept in iced syringes before being processed by a
blood gas analyser (ABL 800, Radiometer, Denmark).
Measurements included Po2 (mmHg), Pco2 (mmHg),
oxygen saturation(%), lactate and haemoglobin (grams
per decilitre). Body O2 consumption (BV˙O2) was
calculated as the product of cardiac output and the
difference in O2 content between arterial and mixed
venous blood, where blood O2 content (μmol ml−1) was
computed as (Hb× 0.621 O2 saturation)+ (0.00131PO2)
(Duncker et al. 2000).
Data analysis
Digital recording and off-line haemodynamic analyses
were described previously (Haitsma et al. 2002). CO
was corrected for body weight (cardiac index, CI). Total
pulmonary vascular resistance index (tPVRi) and systemic
vascular resistance index (SVRi) were calculated as
mPAP/CI andmean arterial pressureMAP/CI respectively.
Stroke volume index was computed as CI divided by heart
rate and body oxygen consumption index (BV˙O2i) as BV˙O2
divided by body weight.
Sacrifice
Upon completion of follow-up, i.e. 12 weeks after
banding or sham surgery, animals were sedated
with I.V. tiletamine/zolazepam (5 mg kg−1), xylazine,
(2.25 mg kg−1) and atropine (1 mg) and anaesthetized
with pentobarbital sodium (I.V. 6–12 mg kg−1 h−1). An
endotracheal tube was placed, and animals were ventilated
with a mixture of O2 and N2 (1:2). Following sternotomy,
the heart was arrested and immediately excised together
with the lungs. Parts of the upper and lower lobe of
the right lung were snap frozen in liquid nitrogen for
molecular analyses, or processed for histology. Other
parts of the upper and lower lobe were placed in cold
Krebs buffer for dissection of pulmonary small arteries for
wire-myograph experiments. The left and right ventricle
of the heart were weighed separately to assess right
ventricular hypertrophy.
Plasma ET measurements
Two-weekly blood samples were collected in EDTA-coated
tubes, centrifuged for 10min at 1460 g and 4°Candplasma
was subsequently aliquoted and cryopreserved at −80°C
until analysis. For measurement of plasma ET levels, an
ET enzyme-linked immunosorbent assay (ELISA)-kit was
used according to the manufacturer’s protocol (Enzo Life
Sciences International Inc., Farmingdale, NY, USA).
Real-time quantitative PCR of lung tissue
For measurement of prepro-ET-1 (PPET), ET converting
enzyme-1 (ECE), ET receptor A (ETA) and ET receptor
B (ETB) mRNA levels, lung tissue was snap frozen in
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liquid nitrogen after excision. Small pieces of tissue
(<30 mg) were homogenized by adding RLT lysis buffer
(Qiagen, Venlo, TheNetherlands) and 2-mercaptoethanol
(Sigma-Aldrich, Zwijndrecht, The Netherlands) using a
homogenizer. After a proteinase K (Invitrogen, Breda,
The Netherlands) treatment at 55°C for 10 min, total
RNA was isolated using RNeasy Fibrous Tissue Mini
Kit (Qiagen). RNA was eluted in RNase-free water and
the concentration was determined using a NanoDrop
(NanoDrop1000, Thermo Fisher Scientific, Bleiswijk,
The Netherlands). RNA integrity was confirmed by
Bioanalyzer (2100 Bioanalyzer, Agilent, Santa Clara, CA,
USA). cDNA was synthesized from 500 ng of total
RNA with SensiFAST cDNA Synthesis Kit (Bioline,
London, UK). RT-qPCR (CFX-96, Bio-Rad, Hercules,
CA, USA) was performed with SensiFAST SYBR &
Fluorescein Kit (Bioline). Target gene mRNA levels were
normalized against β-actin, glyceraldehyde-3-phosphate
dehydrogenase (GADPH) and cyclophilin using the CFX
manager software (Bio-Rad). Relative gene expression
data were calculated using the Ct method. Expression
relative to sham was calculated by dividing individual
expressions of PVB as well as sham animals bymean sham
expression.
Wire myograph experiments
In vitro pulmonary vessel experiments were performed
as previously described (Mulvany & Halpern, 1977;
Zhou et al. 2014). In short, pulmonary small arteries
were dissected and stored overnight in oxygenated (95%
O2–5% CO2) Krebs bicarbonate solution (composition
in mM: 118 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4,
1.2 KH2PO4, 25 NaHCO3, glucose 8.3; pH 7.4) at
4°C. The next day, 2 mm segments were obtained and
mounted on wire myographs in separate organ baths
with oxygenated Krebs–bicarbonate solution at 37°C.
Following a stabilization period of 30 min, internal
vessel diameter was set to a tension equivalent of 0.9
times the estimated diameter at 20 mmHg effective
transmural force. After pre-constriction using 100 nM
of the synthetic thromboxane analogue U46619, endo-
thelial integrity was ascertained by administration of the
endothelium-dependent vasodilator substance P (10 nM).
Maximal constriction was tested by exposure of the vessels
to 100mMKCl. After 30min of stabilization in fresh buffer
solution, vessels were incubatedwith either no blocker, the
ETA blocker BQ123 (10−6 M) or the ETB blocker BQ788
(10−8 M). To test contraction to ET, vessels were sub-
jected to incremental dosages from 10−10 to 3 × 10−7
M ET. Constriction to ET was calculated as percentage of
maximal constriction to 100 mM KCl. Data were analysed
using designated software (Labchart 8.0, ADInstruments,
Sydney, Australia), and concentration–response curves
were created using Prism (version 5.0, GraphPad Software,
Inc., La Jolla, CA, USA) and StatView (version 5.0, SAS
Institute, Cary, NC, USA).
Histology
Tissue from the upper and lower lobe of the right
lung was fixed in 3.5–4% buffered formaldehyde for at
least 48 h and subsequently dehydrated in incremental
alcohol solutions, xylene and finally embedded in
paraffin wax. Transverse sections (4.5 μm) were
cut, using a microtome, and mounted on glass
slides. Resorcin–Fuchsin–von Gieson (RF) staining was
performed to discriminate the internal and external
elastic lamina in small pulmonary arteries. Using the
Hamamatsu NanoZoomer Digital Pathology (NDP) slide
scanner (Hamamatsu Nanozoomer 2.0HT, Hamamatsu
Photonics K.K., Hamamatsu City, Japan), whole section
images were obtained. Morphometric measurements of
pulmonary small arteries were performed using NDP
viewer (Hamamatsu). Both internal and external elastic
lamina areas were measured and assuming circularity of
the vessels, inner and outer radius were calculated as
r = (area/π). Wall-to-lumen ratio was calculated as
(outer − inner radius)/inner radius, and relative lumen
area as outer/inner area. To ensure that pulmonary veins
were excluded from analysis, vessels in close proximity
to the intersegmental septae were excluded from analysis.
Only transversely cut vessels with an outer diameter of
50–150 μm were analysed.
Statistical analysis
SPSS Statistics (version 21.0, IBM Corp., Armonk,
NY, USA) was used for statistical analysis. Statistical
analysis was performed using Student’s t test, or
one-way or two-way ANOVA for repeated measures,
followed by post hoc testing with the Bonferroni test,
when appropriate. Concentration–response curves were
analysed by regression analyses using Prism (version 5)
and Statview (Version 5.0). Statistical significance was
accepted when P  0.05 (two-tailed). Data are presented
as means ± SEM. Individual data below the (1st quartile
– 1.5 × interquartile range) and above the (3rd quartile
+ 1.5 × interquartile range) thresholds were considered
outliers, and were excluded from statistical analyses.
Results
Induction of pulmonary hypertension
Already after 5 weeks, pulmonary vein banding resulted in
an increased tPVRiof 129±6 vs.105±5mmHg l−1 minkg
in sham animals (P 0.05). This increased resistance was
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Figure 1. Progression of mean pulmonary artery pressure (mPAP), cardiac index (CI), total pulmonary
vascular resistance index (tPVRi) and arterial partial oxygen pressure (PO2 ) at rest over time
Values are means ± SEM. Dotted line represents clinical threshold for PH. ∗P  0.05 vs. sham by two-way ANOVA
for repeated measures with Bonferroni posthoc test. PVB, n = 7 for mPAP, n = 6 for CI and tPVRi; Sham, n = 6.
PVB, pulmonary vein banding.
reflected in pulmonary hypertension: mPAP = 29 ± 1 vs.
21± 1 mmHg in sham (P 0.01). Both tPVRi and mPAP
increasedover time, reflecting theprogressivenatureofPH
(Fig. 1; week 12 tPVRi: 255 ± 31 vs. 116 ± 10 mmHg l−1
min kg; mPAP: 39 ± 1 vs. 20 ± 2 mmHg; both P 0.01).
Resting systemic haemodynamics remained unchanged as
compared to sham group (Table 1) and cardiac index,
while transiently higher in the PVB group at week 5 and 7,
Table 1. Haemodynamics at rest and during exercise before and after administration of tezosentan
Exercise (km h−1)
Group Treatment n Rest 2 4
HR (bpm) Sham Control 5 133 ± 10 195 ± 7∗ 256 ± 9∗
Tezosentan 5 160 ± 12‡ 203 ± 13∗ 263 ± 11∗
PVB Control 6 131 ± 7 173 ± 6∗ † 198 ± 6∗ †
Tezosentan 6 145 ± 3 180 ± 5∗ 208 ± 9∗ †
MAP (mmHg) Sham Control 5 96 ± 3 101 ± 2 103 ± 3
Tezo 5 86 ± 4 88 ± 1‡ 95 ± 2‡
PVB Control 6 86 ± 5 86 ± 4† 84 ± 6†
Tezosentan 6 73 ± 3‡ † 77 ± 3‡ † 78 ± 4†
LAP (mmHg) Sham Control 5 3.0 ± 0.5 6.8 ± 0.9 9.0 ± 0.3∗
Tezosentan 5 6.3 ± 2.9 8.8 ± 1.3 13.3 ± 1.0‡
PVB Control 6 5.7 ± 1.4 9.4 ± 1.2∗ 12.8 ± 1.9∗
Tezosentan 6 4.4 ± 1.7 7.8 ± 1.3∗ ‡ 13.7 ± 2.8∗
mPAP (mmHg) Sham Control 5 20 ± 1 30 ± 3∗ 35 ± 3∗
Tezosentan 5 20 ± 2 28 ± 3∗ 35 ± 3∗
PVB Control 6 35 ± 2† 55 ± 4∗ † 59 ± 3∗ †
Tezosentan 6 33 ± 3† 48 ± 4∗ ‡ † 57 ± 3∗ †
CI (l min−1 kg−1) Sham Control 5 0.17 ± 0.01 0.24 ± 0.02∗ 0.28 ± 0.02∗
Tezosentan 5 0.19 ± 0.01 0.24 ± 0.01∗ 0.28 ± 0.02∗
PVB Control 5 0.17 ± 0.01 0.22 ± 0.01∗ 0.23 ± 0.01∗
Tezosentan 5 0.18 ± 0.01 0.22 ± 0.01∗ 0.23 ± 0.01∗
SVi (ml kg−1) Sham Control 5 1.29 ± 0.13 1.23 ± 0.12 1.09 ± 0.11
Tezosentan 5 1.23 ± 0.12 1.20 ± 0.12 1.09 ± 0.10
PVB Control 5 1.28 ± 0.07 1.27 ± 0.08 1.20 ± 0.07
Tezosentan 5 1.25 ± 0.09 1.24 ± 0.08 1.14 ± 0.07
SVRi (mmHg l−1 min kg) Sham Control 5 575 ± 26 437 ± 41∗ 381 ± 28∗
Tezosentan 5 453 ± 29‡ 375 ± 22 343 ± 29
PVB Control 5 522 ± 44 405 ± 33∗ 364 ± 38∗
Tezosentan 5 411 ± 44‡ 351 ± 29‡ 334 ± 25∗
Data are means ± SEM. Haemodynamics obtained 12 weeks after banding. ∗P  0.05 vs. rest; †P  0.05 vs. corresponding sham;
‡P  0.05 vs. corresponding control experiment. CI, cardiac index; HR, heart rate; LAP, mean left atrial pressure; MAP, mean arterial
pressure; mPAP, mean pulmonary arterial pressure; SVi, stroke volume index (CI/HR); SVRi, systemic vascular resistance index (MAP/CI).
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remained essentially similar in both groups (Fig. 1). PVB
resulted in a markedly lower arterial PO2 from 7 weeks
after banding, which persisted until follow-up at 12 weeks
(Table 2; 87 ± 4 vs. 101 ± 4 mmHg; P  0.05) and
arterial oxygen saturation tended to be lower at 12 weeks
(96 ± 1 vs. 98 ± 1%; P = 0.06). Mixed venous PO2
and oxygen saturation, arterial and mixed venous PCO2
and haemoglobin were similar between PVB and sham
animals.
Right ventricular remodelling
At sacrifice, body weight and left ventricle to body weight
ratio were similar between groups (Fig. 2). Both the
right ventricle to body weight ratio (1.74 ± 0.11 vs.
1.29 ± 0.06 g kg−1) and the Fulton index, calculated
as ratio of right ventricular to left ventricular weight
(0.59 ± 0.03 vs. 0.44 ± 0.01 g g−1) were increased,
indicating right ventricular hypertrophy.
Table 2. Blood gas analyses at rest and during exercise before and after administration of tezosentan
Exercise (km h−1)
Group Treatment n Rest 2 4
PO2 art (mmHg) Sham Control 5 101 ± 4 89 ± 4∗ 90 ± 5∗
Tezosentan 5 98 ± 2 95 ± 6 90 ± 5
PVB Control 6 87 ± 4† 69 ± 4∗ † 65 ± 4∗ †
Tezosentan 6 82 ± 3† 67 ± 4∗ † 63 ± 4∗ †
PO2 mv (mmHg) Sham Control 5 42 ± 1 35 ± 1∗ 30 ± 1∗
Tezo 5 46 ± 1‡ 38 ± 2∗ 30 ± 2∗
PVB Control 6 41 ± 2 31 ± 2∗ 27 ± 2∗
Tezosentan 6 42 ± 2 34 ± 2∗ 28 ± 2∗
SaO2 art (%) Sham Control 5 98 ± 1 95 ± 1∗ 96 ± 1
Tezosentan 5 97 ± 1 96 ± 1 96 ± 1
PVB Control 6 96 ± 1 90 ± 3 88 ± 2∗ †
Tezosentan 6 95 ± 1 89 ± 2∗ † 86 ± 3∗ †
SaO2 mv (%) Sham Control 5 55 ± 1 40 ± 2∗ 31 ± 3∗
Tezosentan 5 63 ± 2‡ 48 ± 5∗ ‡ 31 ± 4∗
PVB Control 6 56 ± 2 35 ± 3∗ 25 ± 3∗
Tezosentan 6 58 ± 3 41 ± 2∗ 28 ± 4∗
PCO2 art (mmHg) Sham Control 5 40 ± 2 43 ± 2∗ 37 ± 3
Tezosentan 5 41 ± 2 39 ± 2‡ 35 ± 2∗
PVB Control 6 38 ± 3 37 ± 1† 36 ± 2
Tezosentan 6 40 ± 2 39 ± 2 36 ± 2
PCO2 mv (mmHg) Sham Control 5 49 ± 1 52 ± 2 53 ± 3
Tezosentan 5 47 ± 2 49 ± 2 48 ± 2
PVB Control 6 48 ± 2 47 ± 2 49 ± 3
Tezosentan 6 44 ± 3 43 ± 2 44 ± 3
Hb (g dl−1) Sham Control 5 9.4 ± 0.4 11.0 ± 0.3∗ 11.2 ± 0.3∗
Tezosentan 5 9.9 ± 0.6 10.5 ± 0.2 10.9 ± 0.3
PVB Control 6 9.4 ± 0.7 10.0 ± 0.5 10.4 ± 0.8
Tezosentan 6 9.5 ± 0.6 10.1 ± 0.6 10.6 ± 0.6
Lac art (mmol l−1) Sham Control 5 0.78 ± 0.07 0.88 ± 0.07∗ 1.86 ± 0.28∗
Tezosentan 5 0.72 ± 0.06 0.78 ± 0.05 2.46 ± 0.53∗
PVB Control 6 0.87 ± 0.04 0.80 ± 0.04 1.77 ± 0.33∗
Tezosentan 6 0.83 ± 0.05 0.78 ± 0.05 1.95 ± 0.52
BV˙O2 i (mmol min
−1 kg−1) Sham Control 5 0.43 ± 0.03 0.92 ± 0.08∗ 1.26 ± 0.09∗
Tezosentan 5 0.40 ± 0.03 0.75 ± 0.05∗ 1.25 ± 0.06∗
PVB Control 6 0.42 ± 0.04 0.75 ± 0.03∗ 1.00 ± 0.02∗ †
Tezosentan 6 0.42 ± 0.05 0.65 ± 0.02∗ 0.92 ± 0.01∗ ‡ †
Data are means ± SEM. Blood gas analyses obtained 12 weeks after banding. ∗P  0.05 vs. rest; †P  0.05 vs. corresponding sham;
‡P  0.05 vs. corresponding control. art, arterial; BV˙O2 i, body oxygen consumption index (CI × arterio-venous oxygen difference);
Hb, haemoglobin; Lac, lactate; mv, mixed venous; PO2 , partial oxygen pressure; PCO2 , partial carbon dioxide pressure; SaO2 , oxygen
saturation.
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Response to exercise
At all timepoints during follow-up, exercise up to 4kmh−1
produced an increase in mPAP in sham animals that was
the consequence of an increase in LAP in combination
with an increase in CI, while tPVRi remained essentially
unchanged (Fig. 3). Arterial O2-saturation remained
virtually unaffected in sham animals, but decreased
significantly with exercise in PVB animals (Table 2). From
week 6 until week 10, the exercise-induced increases in
LAP (not shown) and CI (Fig. 3) were similar in PVB and
shamanimals, and although restingmPAP and tPVRiwere
higher in PVB as compared to sham, the exercise-induced
increases in mPAP and tPVRi were similar. In week 12, CI
was lower during exercise in PVB animals than in sham
animals (Fig. 3; CI at 4 kmh−1: 0.23± 0.01 vs. 0.28± 0.02;
P 0.05), which was almost entirely attributed to a lower
heart rate in PVB animals compared to sham animals
(Table 1; heart rate at 4 km h−1: 198 ± 6 vs. 256 ± 9
beats min−1; P  0.05). Despite this attenuated increase
in CI, the exercise-induced increase in mPAP was similar
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Figure 2. Right ventricular mass increased in PVB animals (n = 7) as compared to sham animals (n = 6)
Values are means ± SEM. ∗P  0.05 vs. sham by unpaired t test (two-sided). BW, body weight; LV, left ventricle;
RV, right ventricle.
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Figure 3. Haemodynamic response to exercise in week 6, 8, 10 and 12
Values are means ± SEM. ∗P  0.05 effect exercise; †P  0.05 vs. sham; ‡P = 0.07 effect of exercise two-way
ANOVA for repeated measures. CI, cardiac index; mPAP, mean pulmonary arterial pressure; PVB, pulmonary vein
banding; tPVRi, total pulmonary vascular resistance index.
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in PVB and sham animals, as a result of the higher tPVRi
in PVB animals.
Plasma ET levels and effect of ETA/ETB blockade by
tezosentan
Plasma ET levels were similar in PVB and sham animals
in weeks 6 and 8 (Fig. 4), and ETA/ETB blockade by
tezosentan at rest resulted in vasodilatation that was
similar in PVB and sham groups in week 6 (Fig. 5);
tPVRi: −21 ± 4 vs. −18 ± 7 mmHg l−1 min kg;
not significant) and week 8 (tPVRi: −19 ± 8 vs.
−10 ± 5 mmHg l−1 min kg; not significant). Consistent
with the higher plasma ET levels in PVB as compared
to sham animals in week 10 (Fig. 4), tezosentan-induced
vasodilatation was significantly more pronounced in PVB
than in sham animals at rest at this time point (Fig. 5;
resting tPVRi week 10: −43 ± 5 vs. −8 ± 3 mmHg
l−1 min kg; P  0.01) although this effect waned during
exercise. In week 12, plasma ET levels remained higher in
PVB as compared to sham, and the tezosentan-induced
vasodilatation was now higher in PVB than in sham
animals both at rest (Fig. 5; tPVRi: −33 ± 9 vs.
−12 ± 8 mmHg l−1 min kg; P  0.05) and at all exercise
intensities.
Gene expression
PVB lung tissue showed no change in expression of
the ETA receptor while expression of PPET and ECE
was upregulated (Fig. 6). In the lower lobes, this was
accompanied by a down-regulation of the ETB receptor,
which is theET-clearance receptor,while in theupper lobe,
expressionof theETB receptorwasmaintained.Altogether,
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Figure 4. Plasma ET levels over time in PVB and sham animals
Values are individual animals and means ± SEM. Data below the (1st
quartile – 1.5 × interquartile range) and above the (3rd quartile +
1.5 × interquartile range) thresholds were considered outliers (black
symbols), and were excluded from statistical analyses and from
mean ± SEM calculations. ∗P  0.05 vs. sham by unpaired t test
(two-sided).
these data suggest an increased ET production and a
decreased ET clearance in the lungs and point towards the
lungs as the origin of the increased circulating ET levels.
Pulmonary microvascular structure and function
Histological assessment of small pulmonary arteries
revealed increased wall thickness in PVB as compared to
sham (Fig. 7; 16.1 ± 0.9 vs. 13.6 ± 0.4 μm; P  0.05),
resulting in an increased wall/lumen ratio (0.73± 0.05 vs.
0.54 ± 0.01; P  0.01) and a decreased relative lumen
area (0.36 ± 0.02 vs. 0.44 ± 0.01; P  0.01). To elucidate
the potential difference between the upper and lower
lobes, data were split into four groups, PVB upper lobe,
PVB lower lobe, sham upper lobe and sham lower lobe,
which showed that differences between PVB and sham
groups were essentially similar in both lobes, but reached
statistical significance only in the lower lobes (Fig. 7, lower
panel).
Vasoconstriction in response to KCl (100 mM) and
U46619 was increased in vessels isolated from both upper
and lower lobes from PVB as compared to sham animals
(Fig. 8). These effects reflect the medial hypertrophy of
the pulmonary small arteries observed histologically. End-
othelial function, as determined by vasodilatation to sub-
stance P was similar between upper and lower lobes from
sham animals. In PVB animals, the vasodilator response to
substanceP in theupper lobewas not different from that in
the upper lobe of sham swine. However, vasodilatation to
substance P was significantly reduced in pulmonary small
arteries from the lower lobe of PVB animals (Fig. 8).
Administration of exogenous ET resulted in vaso-
constriction in both sham and PVB animals. While
absolute maximal vasoconstriction to ET was higher in
PVB than in sham animals (16.6 ± 2.4 vs. 9.9 ± 1.6 mN;
P  0.05), constriction relative to maximal KCl-induced
vasoconstriction was lower in PVB (121 ± 10% vs.
161 ± 7%; P  0.01), and sensitivity to ET was reduced
in PVB animals (Fig. 9); logEC50, 8.3 ± 0.2 vs. 7.6 ± 0.2;
P 0.05).
Vessels were incubated with BQ123 or BQ788 to
obtain ETA or ETB blockade, and exposed to exogenous
ET. The resulting concentration–response curves were
compared to those of vessels only exposed to exogenous
ET. Under no condition did BQ788 affect the ET
concentration–response curve, while BQ123 reduced the
ET effects, except in the sham lower lobes (Fig. 10).
Discussion
The main findings in this study are that (i) non-restrictive
banding of the confluence of the lower pulmonary veins
in swine resulted in PH; (ii) within 12 weeks after
banding, the initially isolatedpost-capillaryPHprogressed
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Figure 5. Vasodilatation by ETA/ETB-blocker tezosentan had a more pronounced effect on PVB animals
in week 10 and 12
tPVRi: delta total pulmonary vascular resistance index: tPVRi with tezosentan – tPVRi without tezosentan
Values are means ± SEM. ∗P  0.05 effect exercise; †P  0.05 vs. sham; ‡P  0.05 effect exercise PVB vs. effect
exercise sham by two-way ANOVA. PVB, n = 5; Sham, n = 5. PVB, pulmonary vein banding.
to combined pre-/post-capillary PH with structural and
functional changes inpre-capillarypulmonary vessels; (iii)
from 10weeks after banding until sacrifice at 12 weeks, the
ET pathway was upregulated, actively contributing to the
increased pulmonary vascular resistance.
Model validation
This swine model for group II PH originated in the group
of Ibanez et al. (Garcia-Alvarez et al. 2013; Aguero et al.
2014; Pereda et al. 2014). Todate, pulmonary hypertension
and RV function have been studied under anaesthesia in
this model, and revealed a marked increase in mPAP, PVR
and vessel wall thickness that, after 4 months follow-up,
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Values are means ± SEM. ∗P  0.05, ∗∗P  0.01 by unpaired t test
(two tailed).
resulted in structural and functional changes in the RV
and, in a subset of animals, resulted in RV failure. In
the present study, we performed serial measurements
of systemic and pulmonary haemodynamics and blood
gases in awake swine at rest as well as during graded
treadmill exercise. Moreover, the chronic instrumentation
allows for serial testing of vasoactive compounds – to
study over time the mechanisms that control pulmonary
vascular tone – and the serial collection of blood samples.
The current study demonstrates that this porcine group
II PH model has excellent inter-study and inter-group
reproducibility, as the present findings at 12 weeks (mPAP
and PVR, as well as pulmonary vascular remodelling)
are very similar to those of the Ibanez group at
three months (Garcia-Alvarez et al. 2013; Pereda et al.
2014). The additional chronic instrumentation, and sub-
sequent exercise testing unmasked a mild chronotropic
incompetence that has also been shown in PH (Oliveira
et al. 2017), and has been ascribed to impaired auto-
nomic control (Bristow et al. 1992; Wensel et al. 2009).
The impaired increase in heart rate in PVB vs. sham
resulted in an attenuated increase in cardiac index and
is consistent with the exercise intolerance in group II
PH (Caravita et al. 2017; Oliveira et al. 2017). Clinically,
group II PH comprises a variety of different aetiologies,
including left HF, valvular disease, inflow-/outflow-tract
obstructions, and congenital or acquired pulmonary vein
stenosis. The pulmonary vein banding swine model is
well suited to study the progression and pathophysiology
of all forms of group II PH. With translation to PH as
a result of left HF, with reduced or preserved ejection
fraction, it can be both a drawback and an advantage
that there is no actual left HF. On the one hand, this
model could be missing circulating factors originating
from left HF such as elevated natriuretic peptides and
troponins (Gaggin & Januzzi, 2013), while on the other
hand, we are able to study the isolated pulmonary vascular
pathogenesis of CpcPHwithout influence of the left side of
the heart. A limitation of this swinemodel, however, is that
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the conventional methods of calculating PVR ((mPAP −
PCWP)/CO or (mPAP − LAP)/CO) do not result in true
vascular resistance, as the resistance of the band around
the lower pulmonary veins is also taken into account. Also
the new parameter for differentiation between IpcPH and
CpcPH, i.e. the diastolic pressure gradient, is not directly
applicable in this model. In the present study, tPVRi
(PAP/CI) was used to indicate changes in RV afterload as,
with the current haemodynamic measurements, changes
in vascular resistance of the upper and lower lobes cannot
be distinguished from the changes in resistance induced
by PVB.
Oxygenation
The venous confluence drains both inferior (caudal)
pulmonary lobes, which account for 80% of total lung
mass in swine (Garcia-Alvarez et al. 2013). As the animal
grows while the band maintains a fixed venous stenosis
diameter, blood flow to the lower lobes is gradually
restricted, likely resulting in redistribution of the blood
flow to the middle and upper pulmonary lobes. The
increased flow to these lobes decreases capillary transit
time, reflected by a reduced arterial PO2 and, to a lesser
extent in arterial SO2 , in PVB animals (Yuba, 1971). It
could further be speculated that a decreased diffusion
capacity in swine with PVB contributes to the decreased
oxygenation at rest as is also observed in severe pulmonary
arterial hypertension (PAH) and severe PH in HF (Trip
et al. 2014; Hoeper et al. 2016). However, measurement of
diffusion capacity requires respiratorymask-testingwhich
is technically challenging in swine and was not performed
in the present study.
During exercise, the increase in cardiac output further
decreases transit time, which resulted in decreased arterial
PO2 and arterial O2 saturation in PVB swine. In exercising
sham animals, arterial O2 saturation remained relatively
constant, although arterial PO2 decreased slightly, but
to a lesser extent than in swine with PVB. Tezosentan
did not alter cardiac output, and arterial oxygenation.
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Figure 7. Typical examples (A) and histological assessment of small pulmonary arteries (Ø 50–150 μm)
showing differences in wall thickness, wall/lumen ratio and relative lumen area between PVB and sham
groups (B) and between upper and lower lobes of these groups (C)
Values are means ± SEM. Scale bar: 50 μm. ∗P  0.05 vs. corresponding sham, ∗∗P  0.01 vs. corresponding
sham by two-way ANOVA with the Bonferroni post hoc test when appropriate. [Colour figure can be viewed at
wileyonlinelibrary.com]
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Importantly, the observation that arterial PO2 was
unaffected by tezosentan infusion suggests that tezosentan
did not result in pulmonary oedema.
Pulmonary microvascular remodelling in PH: role of ET
Twelve weeks after induction of pulmonary vein banding,
pulmonary small arteries demonstrated muscularization
and thickening of the vascular wall, resulting in a relative
reduction of the vascular lumen. This finding is consistent
with the observation that pulmonary vascular remodelling
in group II PH mainly consists of medial hypertrophy
and muscularization of arterioles (Dickinson et al. 2013).
Consistent with the increased muscularization, we found
that maximal contraction of these vessels was also
increased, whichwas accompanied by alterations in the ET
pathway, a well-known mediator of vascular remodelling
(Shimoda et al. 2002; Shao et al. 2011; Shimoda &
Laurie, 2013). It has been shown that the ET pathway
is upregulated in PAH (Kawanabe & Nauli, 2011; Galie
et al. 2016). Because of the abluminal release, circulating
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Figure 9. Vasoconstriction by administration of exogenous
endothelin-1 (ET) to isolated small pulmonary arteries
Values are means ± SEM. Data are presented as absolute constriction
(mN, left panel) and as percentage of maximal vasoconstriction by
administration of 100 mM KCl (%, right panel). ∗P  0.05 vs. sham
top, †P  0.05 vs. sham EC50 by regression analyses.
plasma ET levels are thought to be the result, at least in
part, of spillover from the junctions between endothelial
and smooth muscle cells and can therefore not be equated
to ET activity in pathological states (Kawanabe & Nauli,
2011). However, plasma ET levels are upregulated in PAH
and correlate with disease severity and haemodynamics
(Stewart et al. 1991; Giaid et al. 1993).
In addition to increased ET levels, ET signalling may
also be increased via upregulation of ET receptors.
For example, ETA receptors have been reported to be
upregulated, while ETB receptors may be up- or down-
regulated, depending on the type of PH, in clinical and
experimental PH (Gosselin et al. 1997; Bauer et al. 2002;
Sauvageau et al. 2009). We previously showed that in
swinewith PH secondary tomyocardial infarction, plasma
ET levels were increased, and infusion of exogenous
ET resulted in a more pronounced pulmonary vaso-
constriction compared to normal swine (Houweling et al.
2006). This increased response to ET appeared to be the
result of an increased ETA-mediated vasoconstriction.
Also, plasma ET levels are increased in chronic HF, and
correlate with the severity of symptoms and pulmonary
haemodynamics (Cody et al. 1992; Pacher et al. 1996).
This is accompanied by upregulation of ETA and down-
regulation of ETB receptors (Ponicke et al. 1998; Zolk et al.
1999; Staniloae et al. 2004).
The observation that ETA+ETB blockade by tezosentan
producedamorepronouncedvasodilatation inawakePVB
than sham animals confirms increased ET activity in type
II PH in vivo. The present study showed an increased
expression of PPET and ECE in lung tissue, and higher
plasma ET levels in PVB as compared to sham at 10 and
12weeks after PVB.As indicated inFig. 4, twooutlierswere
identified and removed from statistical analyses. Although
this decreased the variation within groups, it did not
alter statistical significance. The increased expression of
PPET and ECE, as well as the increased plasma ET levels,
is consistent with data that show that the lungs are the
primary source of ET-1 (Dupuis et al. 1996a,b), although
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the contribution of other organs cannot be excluded in
the present study as PPET or ECE expression was only
measured in lung tissue. Furthermore, it appeared that the
plasmaET levels decreasedover time in the sham-operated
swine, while these levels in PVB swine increased only
slightly. Swine received the banding or sham surgery at
the age of 3 weeks and were studied until the age of
16 weeks. The observation that in sham animals, plasma
ET levels decreased over time is consistent with decreasing
plasma ET levels over time in the first months after birth
in humans (Yoshibayashi et al. 1991).
The higher plasma ET levels in PVB were accompanied
by a decreased expression of ETB receptors, which
are responsible for ET clearance, in the lower lobes.
In the present study, the ETA receptor was the main
receptor responsible for ET-induced vasoconstriction,
since ETB receptor blockade didnot affect this constriction
in pulmonary small arteries from either sham or
PVB animals. The maximal constriction to exogenous
ET was increased, which likely reflects the increased
muscularization of the pulmonary small arteries, as the
response to KCl was similarly increased. Moreover, the
normalized concentration response curve was shifted to
the right in PVB pulmonary small arteries, suggesting
desensitization of the pulmonary vasculature to ET.
Although this desensitization was not accompanied by
a decrease in ETA receptor expression, it is possible that
changes in pulmonary vascular ETA receptor expression
remained undetected as ET receptor expression was
measured in bulk lung-tissue expression, and hence
expression in endothelial and smooth muscle cells cannot
be distinguished from expression in bronchi and alveoli.
Interestingly, the vasodilator response to ET receptor
blockade with tezosentan was blunted during exercise at
10 weeks, but not at 12 weeks, suggesting progressive
activation of the ET system and/or suppression of
ET-mediated constriction during exercise. The latter is
consistent with our previous findings that during exercise,
nitric oxide blunts the vasoconstrictor effect of ET
(Houweling et al. 2005). The attenuated vasodilatation
to tezosentan during exercise at week 10 might thus be the
result of an increase in nitric oxide during exercise that is
no longer present at 12 weeks after PVB.
Clinical relevance
Our study is the first to show that ET is upregulated in
group II PH without an underlying disease that causes
neurohumoral activation such as myocardial infarction
or HF. The fact that an initially purely mechanical
increase of pulmonary pressure and resistance induces
over-activation of the ET pathway suggests that the ET
pathway might be an interesting target for therapy in this
group of patients.
To date, a number of clinical trials have been performed
with a variety of ET receptor antagonists (ERAs) in
chronic HF, with generally rather disappointing results
(Coletta & Cleland, 2001; Louis et al. 2001; Kalra et al.
2002; Luscher et al. 2002; Anand et al. 2004; Packer
et al. 2005; McMurray et al. 2007; Koller et al. 2017;
Vachiery et al. 2018). It should be noted, however,
that all experimental ERAs were tested in the pre-
sence of conventional medical HF therapy, including
angiotensin converting enzyme inhibitors, β-blockers and
angiotensin II and aldosterone receptor antagonists. It
cannot be excluded that the added effect of ERAs was
limited because of blunted neurohumoral activity by
these other drugs. Indeed, in another clinical study, acute
administration of darusentan produced a dose-dependent
change in CI, SVR, PVR, MAP, mPAP and PCWP when
conventional medical therapy was interrupted (Spieker
et al. 2000), whereas in the HEAT and EARTH trials,
where medication was continued, darusentan produced
no additional pulmonary haemodynamic effects (Luscher
et al. 2002; Anand et al. 2004). Moreover, while in some
clinical trials, ERAs did improve haemodynamic variables,
including PCWP, PVR, SVR, CI and right atrial pressure
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Figure 10. Vasoconstriction by administration of exogenous endothelin-1 (ET) to isolated small
pulmonary arteries of the sham upper and lower lobes, and PVB upper and lower lobes
Values aremeans± SEM. Vessels were first incubatedwith either BQ123 for ETA blockade, BQ788 for ETB blockade,
or no receptor blocker at all. Data are presented as percentage of maximal vasoconstriction by administration of
100 mM KCl. ∗P  0.05 vs. ET, †P = 0.06 by regression analyses.
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(Louis et al. 2001; Luscher et al. 2002; McMurray et al.
2007), none resulted in improved outcome or clinical
status. It is therefore important to note that in the pre-
sent study the acute effect of ERAs were investigated, and
that these results may not directly translate to positive
long-term studies. Future studies are thus required to
investigate the pulmonary effects of chronic therapy with
ERAs in group II PH.
The current guidelines of the European Society of
Cardiology for treatment of group II PH recommend
the treatment of the left ventricle, to optimize volume
status, to take care of co-morbidities and to be cautious
in using pulmonary vasodilators (Galie et al. 2016). We
believe a distinction must be made between group II PH
as a result of left HF and non-HF causes of group II
PH. Non-HF causes of group II PH include pulmonary
vein stenosis, which can be either congenital or as a
result of radiofrequency ablation in treatment of atrial
fibrillation (Latson & Prieto, 2007; Manzar, 2007; Fender
et al. 2016). Pulmonary vein stenosis causes a passive
increase in PVR and mPAP, as was also shown in the
present study. We also observed that the ET pathway
is upregulated as early as 10 weeks after inducing the
stenosis, and that ET contributes to an active increase of
PVR and mPAP. Consequently, inhibiting the ET pathway
could be beneficial in this group of patients to stop
progression from IpcPH to CpcPH, especially because
the most serious adverse effects in the clinical trials in
HF patients (worsening of HF, peripheral/pulmonary
oedema) might not apply to non-HF patients. Recently,
the US Food and Drug Administration approved the
dual receptor antagonist bosentan for treatment of PH
in children. While it will mainly be under investigation
as a treatment of PAH, bosentan could also be utilized in
treatment of children with PH as a result of congenital
pulmonary vein stenosis. The observation in this study
that ET-induced vasoconstriction in isolated pulmonary
small arteries appeared to be entirely dependent on ETA
receptors suggests ETA blockade alonemight be preferable
to dual ERAs.
Conclusions
Banding of the confluence of both inferior pulmonary
veins in swine resulted in a progressive increase in
pulmonary arterial pressure and resistance, which could
be measured from week 5 until week 12 after banding,
in the awake state, by chronic instrumentation. From
week 10 onward, the pulmonary endothelin pathway was
upregulated, likely contributing to pre-capillary activation
of the initially isolated post-capillary pulmonary hyper-
tension and leading to structural and functional vascular
remodelling. Inhibition of the endothelin pathway could
thus potentially provide a pharmacotherapeutic target
for early stage post-capillary pulmonary hypertension,
especially in post-capillary pulmonary hypertension with
normal left heart function.
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